Positive Trial Results#
Can-Fite BioPharma Ltd. recently saw its stock price jump by 18% after announcing encouraging results from a Phase 2a clinical trial for its drug, namodenoson, aimed at treating advanced pancreatic cancer. This trial involved patients who had already undergone multiple treatments.
Study Findings#
The study reported preliminary signs of effectiveness, with more than 30% of patients showing stable disease, meaning their cancer did not worsen. Some patients experienced prolonged treatment durations, with one individual remaining on the therapy for over 16 months. Notably, 35% of patients are still receiving treatment and monitoring, and the drug has shown a good safety profile, aligning with earlier findings.
Company Insights#
Pnina Fishman, the Chairperson and Chief Scientific Officer of Can-Fite, expressed optimism about the results, highlighting the potential for lasting disease stabilization in patients. She noted that a significant number of patients are continuing their treatment, which supports further development of namodenoson for pancreatic cancer.
Future Expectations#
Can-Fite plans to release more detailed efficacy analyses, including metrics like progression-free survival (the length of time during and after treatment that a patient lives with the disease without it getting worse) and overall survival rates in the upcoming months. These results will be shared at a clinical conference, contributing to the ongoing research in cancer treatments. Can-Fite is focused on developing small molecule drugs for various cancers and inflammatory diseases.